Lilly’s weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
By Bhanvi Satija (Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly (NYSE:LLY)’s weight-loss treatment, Zepbound, for obstructive sleep apnea,